Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
Clinical trial NCT03386474 · COMPLETED
Trial details
- NCT number
- NCT03386474
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-15
- Primary completion
- 2018-09-06
- Enrollment
- 151
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.